Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of... see more

Recent & Breaking News (TSXV:TELO)

Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)

Newsfile 3 days ago

Telo Genomics Expands its Strategic Collaboration with Mayo Clinic

Newsfile October 30, 2024

Telo Genomics Presents New Performance Data for Its Smoldering Myeloma Prognostic Test

Newsfile October 22, 2024

Telo Genomics Assessing MRD Status in TELO-DMRD Study

Newsfile September 10, 2024

Telo Genomics Receives CLIA Certification

Newsfile August 13, 2024

Pathologists group accepts Telo Genomics' test for rare blood cancer

Jocelyn Aspa June 18, 2024

Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP

Newsfile June 18, 2024

Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024

Newsfile June 12, 2024

Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology

Newsfile May 30, 2024

Telo Genomics and Emery Pharma collaborate

Jocelyn Aspa May 15, 2024

Telo Genomics and Emery Pharma Announce Collaboration

Newsfile May 15, 2024

Telo Genomics Receives Accreditation from College of American Pathologists

Newsfile April 10, 2024

Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial

Newsfile April 2, 2024

Telo Genomics kick-starts clinical trial for multiple myeloma patients

Jocelyn Aspa February 13, 2024

Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients

Newsfile February 13, 2024

Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US

Newsfile January 30, 2024

Telo Genomics Gears up for American Society of Hematology Conference

Newsfile December 6, 2023

Telo Genomics launches physician-based cancer program in U.S.

Jocelyn Aspa November 16, 2023

Telo Genomics Launches Physician Experience Program in the United States

Newsfile November 16, 2023

Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists

Newsfile November 7, 2023